Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Tuesday. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), Zacks reports. The business had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same period in the previous year, the company earned ($0.35) EPS. Heron Therapeutics updated its FY 2024 guidance to EPS.

Heron Therapeutics Stock Performance

HRTX traded up $0.13 on Thursday, reaching $2.14. The company had a trading volume of 1,768,605 shares, compared to its average volume of 2,618,501. The business has a 50 day simple moving average of $3.20 and a 200 day simple moving average of $2.91. The company has a market cap of $321.64 million, a price-to-earnings ratio of -3.50 and a beta of 1.81. Heron Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.93.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on HRTX shares. Capital One Financial initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, April 23rd. They set an “overweight” rating and a $6.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of Heron Therapeutics in a research report on Wednesday. Finally, Rodman & Renshaw initiated coverage on shares of Heron Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective for the company.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.